Filing Flows › Cytokinetics (CYTK) › Q1 2026
Cytokinetics (CYTK) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Cytokinetics (CYTK) reported revenue of $19.4M for the first quarter 2026 (Q1 2026), up 12-fold from a year earlier and +9% from the quarter before. Operating margin was -948.7%.
Cytokinetics, Q1 2026: revenue $19.4M (12× year over year), operating margin -948.7%, net loss $206M, operating cash flow −$145M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.4M | +9% | 12× |
| Operating profit | −$184M | — | — |
| Net earnings | −$206M | — | — |
| Operating cash flow | −$145M | — | — |
What changed
Revenue was $19.4M in Q1 2026, up 1126% year over year and up 9% from the previous quarter. License and Milestone Revenues was the largest line at 62% of revenue. Collaboration Revenues added $1.1M year over year (up 67%), 6% of the total change.
Operating costs exceeded revenue by $183.6M, an operating margin of -948.7%. Total costs grew 29% against revenue growth of 1126%. The fastest-growing cost line was SG&A (+83%). The quarter ended with a net loss of $206.0M, wider than the previous quarter's $183.0M loss.
Operating cash flow was −$145.5M. Non-cash charges added back $3.4M of depreciation and amortization and $30.4M of share-based compensation. Working capital and other items added $26.8M. Capital expenditures of $5.9M exceeded it, leaving free cash flow of −$151.4M.
Questions
What was Cytokinetics' revenue in the first quarter 2026?
Cytokinetics (CYTK) reported revenue of $19.4M for the first quarter 2026 (Q1 2026), up 12-fold from a year earlier and +9% from the quarter before.
Was Cytokinetics profitable in the first quarter 2026?
Operating loss was $184M (-948.7% of revenue) and net loss $206M.
Source: Cytokinetics 10-Q on SEC EDGAR.